2018 - Page 3 of 16

Stem cell eye drops? Skepticism of American Academy of Stem Cell Physicians (AAOSCP)

November 11, 2018 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 2 Comments

I’ve been hearing more recently about something called the American Academy of Stem Cell Physicians (variously AAOSCP or AASCP). Its name has the sound of an organization like some traditional medical academy such as the American Academy of Internal Medicine, but my sense is that this is a totally different kind of beast. People have …

Stem cell eye drops? Skepticism of American Academy of Stem Cell Physicians (AAOSCP) Read More »

To report a sketchy stem cell clinic, a list of simple, concrete things to do

November 7, 2018 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 5 Comments

The stem cell clinic industry selling unapproved “therapies” is ubiquitous and yet somehow still growing it seems. Many of us are encountering more of them including via ads and the clinics are basically all over the place. What should someone do if they see a stem cell clinic that is particularly concerning? A lot of …

To report a sketchy stem cell clinic, a list of simple, concrete things to do Read More »

Mapping & driving the stem cell ecosystem: key points of my new paper

November 5, 2018 February 24, 2021 / By Professor Paul Knoepfler, Ph.D. / 5 Comments

When you think of an ecosystem, do you imagine something like a forest or jungle full of different organisms? I usually do, but over the last few years I’ve also been thinking about this concept in a different way. I’ve been viewing the broad stem cell arena as an ecosystem. In that spirit, I’ve recently …

Mapping & driving the stem cell ecosystem: key points of my new paper Read More »

Magenta Therapeutics Good News-Bad News Trial Data

November 4, 2018 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 2 Comments

Magenta Therapeutics is a biotech company with a portfolio including stem cell products. Their most well known investigational drug product is an expanded umbilical cord stem cell product called MGTA-456, an “ex-Novartis” product. Magenta just released new trial data on MGTA-456, which I see as a case of good news-bad news, and investors seem to …

Magenta Therapeutics Good News-Bad News Trial Data Read More »

Stem Cells in Space

October 31, 2018 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 6 Comments

CubeLabs-on-the-International-Space-Station.-credit-Twyman-Clements

By Jeanne Loring Stem cells boldly go… Last week at the New York Stem Cell Foundation (NYSCF) conference at Rockefeller University in New York City, we announced our collaborative project to study the effects of microgravity on neurons derived from patient-specific induced pluripotent stem cells. The press release is here. Susan Solomon, the CEO of …

Stem Cells in Space Read More »

Stem cell clinic supplier Liveyon tries to regenerate itself after FDA recall

October 30, 2018 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 33 Comments

You probably remember Liveyon. It’s a marketer of an “umbilical cord stem cell” product that was recently recalled by the FDA. The recall was due to adverse events that may have included E. coli contamination somewhere before it was injected into patients, some of whom apparently got sick. Since it seemed like this recalled product was …

Stem cell clinic supplier Liveyon tries to regenerate itself after FDA recall Read More »

Anversa debacle vs. STAP cell train wreck & what’s next

October 28, 2018 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 3 Comments

Remember when the Piero Anversa situation first made news or at least when you first heard about it? In the public domain, it was back around April 2014. I didn’t even do a whole post on it, but rather it made two bullet points in a post about a set of bad overall news including the latest …

Anversa debacle vs. STAP cell train wreck & what’s next Read More »

Polls on futures of stem cell clinics sued by FDA

October 24, 2018 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 11 Comments

Take our poll: what will be the fates of the stem cell clinic firms sued by the FDA one year from now in October 2019? To be clear, I am asking for your predictions, not what you hope will be the situation a year from now. U.S. Stem Cell, Inc. (USRM) and California Stem Cell …

Polls on futures of stem cell clinics sued by FDA Read More »

Stem cells for autism: time to hit pause in 2018?

October 22, 2018 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 9 Comments

Stem cells for autism? After watching this area for many years, I’m not sure there’s any “there there”. There are logical reasons to think that certain stem cells might help many specific diseases, but in my view autism isn’t likely to be one of them. I hope I’m wrong, but today at least in 2018, …

Stem cells for autism: time to hit pause in 2018? Read More »

101-year old lady cured? Groundbreaking FTC Action on Stem Cell Clinic Marketing

October 18, 2018 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 9 Comments

The Federal Trade Commission (FTC) took some strong action against specific stem cell clinics today and the physician behind them. I see this as really good news and it’s something I’ve been pushing for years. The clinics in question in part marketed unproven stem cells for sick kids. Frankly, iffy for-profit stem cell “treatments” for …

101-year old lady cured? Groundbreaking FTC Action on Stem Cell Clinic Marketing Read More »

Year: 2018